|
1
|
World Health Organization: International
Agency for Research on Cancer: Cervical Cancer - Estimated
Incidence. Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/old/FactSheets/cancers/cervix-new.asp.
Accession date: 2016-9-10.
|
|
2
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
Cervical Cancer Version 1. 2013, https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
Accession date: 2016-9-10.
|
|
3
|
Monk BJ, Sill MW, McMeekin DS, Cohn DE,
Ramondetta LM, Boardman CH, Benda J and Cella D: Phase III trial of
four cisplatin-containing doublet combinations in stage IVB,
recurrent, or persistent cervical carcinoma: A Gynecologic Oncology
Group study. J Clin Oncol. 27:4649–4655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thigpen T: The role of chemotherapy in the
management of carcinoma of the cervix. Cancer J. 9:425–432. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kato R, Hasegawa K, Achiwa Y, Okamoto H,
Torii Y, Oe S and Udagawa Y: Predicting nedaplatin sensitivity of
cervical cancer using the histoculture drug response assay. Eur J
Gynaecol Oncol. 32:381–386. 2011.PubMed/NCBI
|
|
6
|
Yamamoto K, Kokawa K, Umesaki N, Nishimura
R, Hasegawa K, Konishi I, Saji F, Nishida M, Noguchi H and Takizawa
K: Phase I study of combination chemotherapy with irinotecan
hydrochloride and nedaplatin for cervical squamous cell carcinoma:
Japanese gynecologic oncology group study. Oncol Rep. 21:1005–1009.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watanabe Y, Nakai H, Etoh T, Kanemura K,
Tsuji I, Ishizu A and Hoshiai H: Feasibility study of docetaxel and
nedaplatin for recurrent squamous cell carcinoma of the uterine
cervix. Anticancer Res. 28(4C): 2385–2388. 2008.PubMed/NCBI
|
|
8
|
Sultana H, Kigawa J, Kanamori Y, Itamochi
H, Oishi T, Sato S, Kamazawa S, Ohwada M, Suzuki M and Terakawa N:
Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients
with uterine cervical cancer. Ann Oncol. 14:214–219. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao Y and Srivastava D: A developmental
view of microRNA function. Trends Biochem Sci. 32:189–197. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stefani G and Slack FJ: Small non-coding
RNAs in animal development. Nat Rev Mol Cell Biol. 9:219–230. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taipaleenmäki H, Bjerre Hokland L, Chen L,
Kauppinen S and Kassem M: Mechanisms in endocrinology: Micro-RNAs:
targets for enhancing osteoblast differentiation and bone
formation. Eur J Endocrinol. 166:359–371. 2012. View Article : Google Scholar
|
|
13
|
Vimalraj S and Selvamurugan N: MicroRNAs:
Synthesis, gene regulation and osteoblast differentiation. Curr
Issues Mol Biol. 15:7–18. 2013.
|
|
14
|
Ni CW, Qiu H and Jo H: MicroRNA-663
upregulated by oscillatory shear stress plays a role in
inflammatory response of endothelial cells. Am J Physiol Heart Circ
Physiol. 300:H1762–H1769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guan YJ, Yang X, Wei L and Chen Q:
miR-365: A mechanosensitive microRNA stimulates chondrocyte
differentiation through targeting histone deacetylase 4. FASEB J.
25:4457–4466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liang D, Xu X, Deng F, Feng J, Zhang H,
Liu Y, Zhang Y, Pan L, Liu Y, Zhang D, et al: miRNA-940 reduction
contributes to human Tetralogy of Fallot development. J Cell Mol
Med. 18:1830–1839. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rajendiran S, Parwani AV, Hare RJ,
Dasgupta S, Roby RK and Vishwanatha JK: MicroRNA-940 suppresses
prostate cancer migration and invasion by regulating MIEN1. Mol
Cancer. 13:2502014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song B, Zhang C, Li G, Jin G and Liu C:
miR-940 inhibited pancreatic ductal adenocarcinoma growth by
targeting MyD88. Cell Physiol Biochem. 35:1167–1177. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang HW, Liu GH, Liu YQ, Zhao HC, Yang Z,
Zhao CL, Zhang XF and Ye H: Over-expression of microRNA-940
promotes cell proliferation by targeting GSK3β and sFRP1 in human
pancreatic carcinoma. Biomed Pharmacother. 83:593–601. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang K, Tang Y, He L and Dai Y:
MicroRNA-340 inhibits prostate cancer cell proliferation and
metastasis by targeting the MDM2-p53 pathway. Oncol Rep.
35:887–895. 2016.PubMed/NCBI
|
|
21
|
Lin SY, Chang CH, Wu HC, Lin CC, Chang KP,
Yang CR, Huang CP, Hsu WH, Chang CT and Chen CJ: Proteome profiling
of urinary exosomes identifies alpha 1-antitrypsin and H2B1K as
diagnostic and prognostic biomarkers for urothelial carcinoma. Sci
Rep. 6:344462016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma J, Sun F, Li C, Zhang Y, Xiao W, Li Z,
Pan Q, Zeng H, Xiao G, Yao K, et al: Depletion of intermediate
filament protein Nestin, a target of microRNA-940, suppresses
tumorigenesis by inducing spontaneous DNA damage accumulation in
human nasopharyngeal carcinoma. Cell Death Dis. 5:e13772014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Weber CEM, Luo C, Hotz-Wagenblatt A,
Gardyan A, Kordass T, Holland-Letz T, Osen W and Eichmüller SB:
miR-339-3p is a tumor suppressor in melanoma. Cancer Res.
76:3562–3571. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hasegawa K, Kato R, Torii Y, Ichikawa R,
Oe S and Udagawa Y: The relationship between ERCC1 expression and
clinical outcome in patients with FIGO stage I to stage II uterine
cervical adenocarcinoma. Int J Gynecol Cancer. 21:1479–1485. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung HH, Kim MK, Kim JW, Park NH, Song
YS, Kang SB and Lee HP: XRCC1 R399Q polymorphism is associated with
response to platinum-based neoadjuvant chemotherapy in bulky
cervical cancer. Gynecol Oncol. 103:1031–1037. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ozen M, Creighton CJ, Ozdemir M and
Ittmann M: Widespread deregulation of microRNA expression in human
prostate cancer. Oncogene. 27:1788–1793. 2008. View Article : Google Scholar
|
|
27
|
Tamguney T and Stokoe D: New insights into
PTEN. J Cell Sci. 120:4071–4079. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Martin J and Dufour JF: Tumor suppressor
and hepatocellular carcinoma. World J Gastroenterol. 14:1720–1733.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK,
Ahsan H, Chen CJ, Lee PH, Peacocke M, Santella RM, et al:
PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene.
18:3181–3185. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Slipicevic A, Holm R, Nguyen MT, Bøhler
PJ, Davidson B and Flørenes VA: Expression of activated Akt and
PTEN in malignant melanomas: Relationship with clinical outcome. Am
J Clin Pathol. 124:528–536. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Z, Stokoe D, Kane LP and Weiss A: The
inducible expression of the tumor suppressor gene PTEN promotes
apoptosis and decreases cell size by inhibiting the PI3K/Akt
pathway in Jurkat T cells. Cell Growth Differ. 13:285–296.
2002.PubMed/NCBI
|
|
32
|
Weng LP, Brown JL and Eng C: PTEN
coordinates G(1) arrest by down-regulating cyclin D1 via its
protein phosphatase activity and up-regulating p27 via its lipid
phosphatase activity in a breast cancer model. Hum Mol Genet.
10:599–604. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chu IM, Hengst L and Slingerland JM: The
Cdk inhibitor p27 in human cancer: Prognostic potential and
relevance to anticancer therapy. Nat Rev Cancer. 8:253–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
le Sage C, Nagel R and Agami R: Diverse
ways to control p27Kip1 function: miRNAs come into play. Cell
Cycle. 6:2742–2749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chu I, Sun J, Arnaout A, Kahn H, Hanna W,
Narod S, Sun P, Tan CK, Hengst L and Slingerland J: p27
phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell.
128:281–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pateras IS, Apostolopoulou K, Koutsami M,
Evangelou K, Tsantoulis P, Liloglou T, Nikolaidis G, Sigala F,
Kittas C, Field JK, et al: Downregulation of the KIP family members
p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in
p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer.
119:2546–2556. 2006. View Article : Google Scholar : PubMed/NCBI
|
